201 related articles for article (PubMed ID: 34063098)
1. Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer.
Saghaeidehkordi A; Chen S; Yang S; Kaur K
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34063098
[TBL] [Abstract][Full Text] [Related]
2. Peptide-Drug Conjugate Targeting Keratin 1 Inhibits Triple-Negative Breast Cancer in Mice.
Ziaei E; Paiva IM; Yao SJ; Sarrami N; Mehinrad P; Lai J; Lavasanifar A; Kaur K
Mol Pharm; 2023 Jul; 20(7):3570-3577. PubMed ID: 37307328
[TBL] [Abstract][Full Text] [Related]
3. Targeting Triple Negative Breast Cancer Cells with Novel Cytotoxic Peptide-Doxorubicin Conjugates.
Ziaei E; Saghaeidehkordi A; Dill C; Maslennikov I; Chen S; Kaur K
Bioconjug Chem; 2019 Dec; 30(12):3098-3106. PubMed ID: 31715102
[TBL] [Abstract][Full Text] [Related]
4. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
5. A Novel Homodimer Peptide-Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy.
Liu S; Tian Y; Jiang S; Wang Z
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902021
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
7. Trojan-Like Peptide Drug Conjugate Design and Construction for Application in Treatment of Triple-Negative Breast Cancer.
Xiao C; Han J; Bai J; Xia Y; Wang S
J Biomed Nanotechnol; 2021 Aug; 17(8):1554-1563. PubMed ID: 34544533
[TBL] [Abstract][Full Text] [Related]
8. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
[TBL] [Abstract][Full Text] [Related]
9. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
[TBL] [Abstract][Full Text] [Related]
10. Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC.
Kim HR; Cho YS; Chung SW; Choi JU; Ko YG; Park SJ; Kim SY; Byun Y
J Control Release; 2022 Jun; 346():136-147. PubMed ID: 35447298
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment.
Khondee S; Chittasupho C; Tima S; Anuchapreeda S
Curr Drug Deliv; 2018; 15(3):406-416. PubMed ID: 28707580
[TBL] [Abstract][Full Text] [Related]
12. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
Sheng Y; You Y; Chen Y
Int J Pharm; 2016 Oct; 512(1):1-13. PubMed ID: 27521706
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-Bound Hydroxyethyl Starch Conjugate Nanoparticles with pH/Redox Responsive Linkage for Enhancing Antitumor Therapy.
Tan R; Tian D; Liu J; Wang C; Wan Y
Int J Nanomedicine; 2021; 16():4527-4544. PubMed ID: 34276212
[TBL] [Abstract][Full Text] [Related]
14. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.
Ai S; Duan J; Liu X; Bock S; Tian Y; Huang Z
Mol Pharm; 2011 Apr; 8(2):375-86. PubMed ID: 21241067
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer.
You Y; Xu Z; Chen Y
Drug Deliv; 2018 Nov; 25(1):448-460. PubMed ID: 29405790
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice.
Yang F; Ai W; Jiang F; Liu X; Huang Z; Ai S
J Pharm Sci; 2016 Feb; 105(2):639-649. PubMed ID: 26869425
[TBL] [Abstract][Full Text] [Related]
17. Nano-delivery vehicle based on chlorin E6, photodynamic therapy, doxorubicin chemotherapy provides targeted treatment of HER-2 negative, ανβ3-positive breast cancer.
He Z; Jiang H; Zhang X; Zhang H; Cui Z; Sun L; Li H; Qian J; Ma J; Huang J
Pharmacol Res; 2020 Oct; 160():105184. PubMed ID: 32946931
[TBL] [Abstract][Full Text] [Related]
18. A Novel Strategy Conjugating PD-L1 Polypeptide With Doxorubicin Alleviates Chemotherapeutic Resistance and Enhances Immune Response in Colon Cancer.
Wang M; Shu XS; Li M; Zhang Y; Yao Y; Huang X; Li J; Wei P; He Z; Lu J; Ying Y
Front Oncol; 2021; 11():737323. PubMed ID: 34858817
[TBL] [Abstract][Full Text] [Related]
19. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
20. Formation of ssDNA nanotubes from spherical micelles and their use as a delivery vehicle for chemotherapeutics and senolytics to triple negative breast cancer cells.
Lin L; Schneiderman Z; Venkatraman A; Kokkoli E
Nanoscale; 2023 Jun; 15(22):9801-9812. PubMed ID: 37200016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]